100 innovations that can transform beauty, #8: “If established companies want access to breakthrough innovation, they need to become more involved in developing it,” says co-founder and CEO Chris Christiansen.
Copenhagen-based biotech startup Lifebloom is developing a new generation of ingredients for the personal care industry using cyanobacteria, microscopic organisms that have inhabited the planet for billions of years.
– These remarkable organisms, co-founder and CEO Chris Christiansen shares, use sunlight and carbon dioxide to produce valuable molecules, offering an alternative to ingredients traditionally sourced from fossil feedstocks and agricultural crops such as oil palm. We’re combining biotechnology with a deep understanding of the personal care industry to create ingredients that are functionally relevant, bio-based and biodegradable. Our ambition is to prove that the most sustainable ingredients can also be among the best performing.
According to Christiansen, one striking thing about the industry is how easily a plausible scientific mechanism can become an accepted marketing claim.
– We regularly see ingredient suppliers presenting impressive laboratory data demonstrating effects on isolated cells, alongside clinical results showing improvements in skin appearance. Both sets of results may be entirely valid, but they don’t necessarily prove that the proposed cellular mechanism is responsible for the clinical outcome, he says, continuing,
– Often missing is evidence that the ingredient actually reaches its intended biological target and delivers the claimed effect when applied to the skin under real-world conditions. My point is not that laboratory studies aren’t valuable. Quite the opposite. But we should be careful to distinguish between what we have demonstrated scientifically and what remains a hypothesis. In our organisation, we try to hold ourselves to that same standard.
What is it like being a biotech startup in 2026?
– Probably more challenging than most people imagine. Biotechnology has enormous potential to transform how we manufacture materials and ingredients. At the same time, it’s an unforgiving industry in which scientific breakthroughs don’t automatically translate into commercially viable products. You can spend years developing a molecule, only to discover that scaling production is too expensive, purification is too complicated, or customers aren’t willing to pay for the additional performance.
– I also think we’re seeing a necessary correction in biotech. For years, the industry attracted substantial investment on the promise of what biology could eventually make possible. Today, there’s a much stronger demand for tangible commercial progress. Personally, I think that’s healthy.
Price parity can often be a critical thing to be able scale. What’s your view on that?
– I think it is important, but also often misunderstood. If we’re developing a direct replacement for an existing commodity ingredient, without offering any additional functionality, then of course we need to compete on price. Sustainability alone doesn’t justify a significant premium at scale.
But ingredient buyers don’t compare prices per kilogram. What matters is the cost of delivering a particular function in the final formulation. An ingredient costing three times as much per kilogram could still be the more economical option if it works at one-tenth the concentration, replaces multiple ingredients or enables a product benefit that competitors cannot offer.
– For us, Christiansen explains, the challenge is therefore twofold. Develop a production process that becomes increasingly cost-efficient as we scale, while demonstrating functionality that makes our ingredients commercially attractive. The next generation of bio-based ingredients will not succeed by being greener versions of what already exists. They need to give formulators and brands another compelling reason to switch.
You’re not fully market-ready yet. Can you share a roadmap to market launch?
– We’re currently moving from laboratory development towards pilot-scale production and commercial validation.
– Over the past year, we’ve narrowed our focus to one particularly promising ingredient, which we’re developing through our proprietary extraction and purification process. Our immediate priorities are demonstrating consistent kilogram-scale production, establishing the necessary quality and safety documentation, and generating convincing evidence of its performance in cosmetic formulations.
– We’re targeting larger pilot production during 2027 and working towards initial commercial applications with industry partners. The exact timing of a broader market launch will depend on successfully validating the production process and completing the necessary testing. We’re deliberately taking a stepwise approach rather than rushing an ingredient to market before we’re confident that it delivers real value.
What would a typical use case be?
– We’re initially developing ingredients for skin and hair care, with a particular interest in supporting hydration, barrier function, and resilience.
– What makes our approach interesting is that we’re looking beyond conventional cosmetic functionality. We want to understand how naturally occurring biological molecules can interact with the skin and deliver meaningful benefits, rather than simply adding another ingredient to an already crowded formulation.
– We’re also exploring opportunities to develop functional ingredients that help other cosmetic actives perform better, for instance by improving their stability, solubility, or delivery. Ultimately, our ambition is to build a broader ingredient platform, where we can develop different molecules and functionalities from the same biological starting point.

Chris Christiansen’s extra industry insights
– One of my biggest observations is that the personal care industry has a risk problem. We meet highly capable scientists, ingredient developers, and product innovators all the time. There’s no shortage of ideas or promising technologies. But introducing a new ingredient involves uncertainty. Brands need regulatory confidence, proven performance, reliable supply, competitive economics, and assurance that the supplier will still be around in five years.
– These are perfectly legitimate requirements. The problem arises when every individual company wants someone else to take the early risk. Startups are expected to demonstrate industrial scale before customers commit to meaningful volumes. But building industrial scale requires investment, and investment often depends on evidence of customer demand. It’s a difficult cycle to break.
– I believe that if established companies want access to breakthrough innovation, they need to become more involved in developing it. That means earlier commercial commitments, shared development projects and a willingness to test promising technologies before every risk has been eliminated.
– Another important point is that sustainability and functionality need to stop being treated as separate conversations. We’ve spent years discussing whether bio-based ingredients can match the performance of conventional chemistry. I think the more interesting question is where biology can outperform it. That’s where new ingredient categories will emerge.
– I’m particularly fascinated by how little we’ve explored the potential of microorganisms as chemical factories. Cyanobacteria have existed for billions of years, and their metabolism contains an enormous diversity of molecules and biochemical pathways. Yet the modern personal care industry still depends heavily on a relatively narrow selection of traditional feedstocks. My hope is that, in the future, we won’t distinguish between sustainable ingredients and high-performance ingredients. The best ingredients will simply be both.
Words: Johan Magnusson
100 innovations that can transform beauty, #1: Watch this space: a next-gen refill solution is here
100 innovations that can transform beauty, #2: Enzymes reshape plastic recycling as we know it, here’s how
100 innovations that can transform beauty, #3: Seaweed beauty packaging innovation is only weeks away from launching, on an industrial scale
100 innovations that can transform beauty, #4: How this new lightweight liquid package can transform refill solutions for beauty and personal care brands
100 innovations that can transform beauty, #5: How to create fibre-based closures at cost parity with plastic alternatives
100 innovations that can transform beauty, #6: What if recycling of plastic and polyester didn’t turn them into lower-grade materials?
100 innovations that can transform beauty, #7: How forestry by-products can make large-scale industrial cosmetic manufacturing more efficient

